HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rolf Bohlmann Selected Research

ZK253

2/2004Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rolf Bohlmann Research Topics

Disease

4Neoplasms (Cancer)
12/2021 - 02/2004
1Aneuploidy (Aneuploid)
01/2020
1Postmenopausal Osteoporosis
07/2008
1Breast Neoplasms (Breast Cancer)
02/2004

Drug/Important Bio-Agent (IBA)

2Hormones (Hormone)IBA
07/2008 - 02/2004
2Estrogen ReceptorsIBA
07/2008 - 02/2004
1Positive Transcriptional Elongation Factor BIBA
12/2021
1Phosphotransferases (Kinase)IBA
01/2020
1atuveciclibIBA
11/2017
1LigandsIBA
07/2008
1Estrogens (Estrogen)FDA Link
02/2004
1ZK253IBA
02/2004
1TamoxifenFDA LinkGeneric
02/2004
1ZK703IBA
02/2004
1Urea (Carbamide)FDA LinkGeneric
02/2004
1Selective Estrogen Receptor Modulators (SERM)IBA
02/2004
1Estrogen Receptor Modulators (Antiestrogen)IBA
02/2004
1Fulvestrant (Faslodex)FDA Link
02/2004

Therapy/Procedure

3Therapeutics
12/2021 - 07/2008
1Aftercare (After-Treatment)
02/2004